# OnCo record jur-003 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/jur-003/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "jur-003" ;
  schema:name "JUR-003"@en ;
  schema:description "JUR-003 is an experimental biologic from Juri Biosciences, in phase 1 trials for metastatic castration-resistant prostate cancer, metastatic hormone-sensitive prostate cancer and oligometastatic prostate cancer."@en ;
  schema:url <https://onco.cc/drugs/jur-003/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/api/v2/studies/NCT07824349>, <https://clinicaltrials.gov/api/v2/studies/NCT07824349>, <https://markets.financialcontent.com/wral/article/gnwcq-2025-5-27-juri-biosciences-a-tcg-labs-soleil-portfolio-company-and-epimab-biotherapeutics-enter-into-a-worldwide-licensing-agreement-for-klk2-directed-t-cell-engager-in-metastatic-prostate-cancer>, <https://clinicaltrials.gov/search?intr=JUR-003> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Biologic (T-cell engager per OnCo text; registry says only 'Biological')" ;
  onco:cancers <https://onco.cc/cancers/prostate-mcrpc/>, <https://onco.cc/cancers/prostate-mhspc/>, <https://onco.cc/cancers/prostate/> ;
  onco:companies <https://onco.cc/companies/juri-biosciences/> ;
  onco:trials <https://onco.cc/trials/nct07824349/> .